Pancreatic cancer pill daraxonrasib shows 61% response rate in early trial
A new KRAS-targeted oral drug, daraxonrasib, shrank tumors in a majority of patients with advanced pancreatic and lung cancers in an early-stage trial, with some tumors disappearing entirely. Experts are calling it a potential major breakthrough in pancreatic cancer treatment.